# Study Evaluating Fosfomycin/Tobramycin for Inhalation in Cystic Fibrosis Patients With Pseudomonas Aeruginosa Lung Infection

> **NCT00794586** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 120 (estimated)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** FTI, AZLI
- **DRUG:** Placebo, AZLI

## Key facts

- **NCT ID:** NCT00794586
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2010-02
- **Final completion:** 2010-03
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2013-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00794586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00794586, "Study Evaluating Fosfomycin/Tobramycin for Inhalation in Cystic Fibrosis Patients With Pseudomonas Aeruginosa Lung Infection". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT00794586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*